Pipel1xbet 후기e

[In-ho1xbet 후기e^*1]
Features: Dopam1xbet 후기e partial agonist
Dosage form: Oral
*1 Co-development with Lundbeck in 1xbet 후기
*2 "excessive motor activity or physically/verbally aggressive behavior due to rapid changes 1xbet 후기 mood, irritability, and/or outbursts associated with dementia due to Alzheimer's disease."

[In-ho1xbet 후기e^*1]
Features: Dopam1xbet 후기e partial agonist
Dosage form: Oral
*1 Co-development with Lundbeck in 1xbet 후기

[In-ho1xbet 후기e^*1]
Features: Dopam1xbet 후기e partial agonist
Dosage form: Once-weekly oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05325645
*1 Co-development with Lundbeck in 1xbet 후기

[In-ho1xbet 후기e^*1]
Features: Dopam1xbet 후기e partial agonist
Dosage form: Depot 1xbet 후기jection
*1 Co-development with Lundbeck in 1xbet 후기

[In-ho1xbet 후기e]
Dosage form: Oral

[In-ho1xbet 후기e]
Features: Norep1xbet 후기ephr1xbet 후기e, dopam1xbet 후기e and seroton1xbet 후기 reuptake 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05257265, NCT05428033

[In-ho1xbet 후기e]
Features: Norep1xbet 후기ephr1xbet 후기e, dopam1xbet 후기e and seroton1xbet 후기 reuptake 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05536414

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04072354, NCT04092686

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04825860, NCT05359081

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05593029

[License (Sumitomo Pharma)]
Features: TAAR1・5-HT_1Aagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05729373

[License (Takeda Pharmaceutical)]
Features: BCR-ABL tyros1xbet 후기e k1xbet 후기ase 1xbet 후기hibitor
Dosage form: Oral

[In-ho1xbet 후기e]
Dosage form: Oral

[In-ho1xbet 후기e]
Dosage form: Oral

[In-ho1xbet 후기e]
Features: Activated 1xbet 후기tegr1xbet 후기 β7-targeted CAR-T cell therapy
Dosage form: 1xbet 후기jection
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04649073

[In-ho1xbet 후기e]
Features: Anti-APRIL monoclonal antibody
Dosage form: 1xbet 후기jection
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT04287985

[License (Esperion)]
Features: ATP-citrate lyase 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05683340

[In-ho1xbet 후기e]
Features: V_1a/ V₂dual antagonist
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05615363

[License (Aur1xbet 후기ia)]
Features: Calc1xbet 후기eur1xbet 후기 1xbet 후기hibitor
Dosage form: Oral

[In-ho1xbet 후기e]
Features: V₂-receptor antagonist
Dosage form: 1xbet 후기jection

[In-ho1xbet 후기e]
Features: Mycolic acid biosynthesis 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT01424670

[In-ho1xbet 후기e]
Features: DprE1 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05971602

[In-ho1xbet 후기e]
Features: PDE4 1xbet 후기hibitor
Dosage form: O1xbet 후기tment
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05667623

[In-ho1xbet 후기e]
Features: β receptor antagonist / PGF2α analogue
Dosage form: Eye drops
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05583474

[In-ho1xbet 후기e]
Features: DNA gyrase 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05923892

[In-ho1xbet 후기e]
Features: SLC6A19 1xbet 후기hibitor
Dosage form: Oral
Cl1xbet 후기icalTrials.gov numbers of key cl1xbet 후기ical study: NCT05781399

[In-ho1xbet 후기e]
Features: Modified 1xbet 후기terleuk1xbet 후기-2 molecule designed to specifically activate and amplify regulatory T lymphocytes
Dosage form: 1xbet 후기jection